BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OnSource Corporation (OSCE.OB) Announces Letter Of Intent To Merge With Osmotics Pharma, Inc.; Provides For Entry Into Specialty Pharmaceuticals


10/19/2005 5:12:16 PM

BOULDER, Colo.--(BUSINESS WIRE)--Jan. 14, 2005--OnSource Corporation ("OnSource") (OTCBB:OSCE), today announced that it entered into a non-binding Letter of Intent to merge with Osmotics Pharma, Inc. ("OPI"). OPI is an emerging specialty pharmaceutical company focused on developing prescription products for the treatment of dermatological disorders, antibiotic resistant bacterial infections and certain cancers (www.osmotics.com/pharma_press.aspx). OPI has the exclusive worldwide rights covering technologies developed by the University of California and Brigham Young University. Applications of these technologies are currently being tested by some of the leading research institutions in the world. All of OPI's products are in the development stage and subject to approval by the United States Food and Drug Administration. OPI is a subsidiary of Osmotics Corporation, a privately held company selling premium cosmeceutical products primarily through prestige retailers (www.osmotics.com).

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES